Metastatic bladder cancer is an aggressive malignancy with a poor prognosis when presenting with advanced stage. Cisplatin-based therapy has been the mainstay of first-line treatment but therapy in second-line setting has been an unmet medical need for decades. Moreover, many patients are unable to receive cisplatin-based therapy. Recently, immune-checkpoint inhibitors transformed the management and prognosis of many malignancies and will certainly redefine the standard of care for bladder cancer. Atezolizumab, an antiprogrammed cell death ligand-1 antibody, was the first immune-checkpoint inhibitor to be approved by the US FDA in May 2016 for patients with urothelial carcinoma. In this review, we discuss the evidence behind this promising drug.
Future oncology (London, England). 2017 Nov 14 [Epub ahead of print]
Zineb Hamilou, Pernelle Lavaud, Yohann Loriot
Department de Médecine Oncologique & INSERM U981, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.